These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6394871)

  • 1. [Use of Albetol for treating hypertension patients].
    Kharchenko VI; Savenkov PM; Evsikov EM
    Kardiologiia; 1984 Sep; 24(9):104-9. PubMed ID: 6394871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinico-experimental study of the new antihypertensive preparation abletol (labetalol)].
    Glezer GA; Smolenskiĭ VS; Porotikov VI; Meĭler SM; Khodzhamirova VS
    Kardiologiia; 1983 Aug; 23(8):12-6. PubMed ID: 6137588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic effects of long-term oral labetalol.
    Edwards RC; Raftery EB
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):733-6. PubMed ID: 791328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypotensive effect and changes of arterial pressure variability induced by treatment with labetalol in patients with slight and moderate arterial hypertension].
    Palatini P; Pessina AC; Sperti G; Ventura E; Agnoletto V; Semplicini A; Hlede M; Gava R; Mormino P; Dal Palù C
    G Ital Cardiol; 1983; 13(1):18-22. PubMed ID: 6873535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypotensive effect of a single daily dose of labetalol: a preliminary study.
    Rossi A; Ziacchi V; Lomanto B
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):438-45. PubMed ID: 6754634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of hypertension: amelioration of left ventricular performance by treatment with labetalol.
    Belogi M; Ansuini R; Pupita G; Campolucci G; Pupita F
    Int J Clin Pharmacol Res; 1984; 4(5):385-7. PubMed ID: 6519853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Labetalol in the treatment of arterial hypertension. A Brazilian multicenter study].
    Benchimol AB; Sbissa AS; Benchimol CB; Saad EA; Barbosa ET; Albanesi Filho FM; Pillegi F; da Cunha GP; Maranhão MF; Batlouni M; Schlesinger P; Duprat R; Maciel R
    Arq Bras Cardiol; 1982 May; 38(5):421-7. PubMed ID: 6762868
    [No Abstract]   [Full Text] [Related]  

  • 8. Labetalol in essential hypertension.
    Larochelle P; Hamet P; Hoffman B; Kuchel O; McKenzie J; Mitenko P; Ogilvie RI; Ruedy J
    J Cardiovasc Pharmacol; 1980; 2(6):751-9. PubMed ID: 6160325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of arterial hypertension with labetalol. A polycentric study].
    G Ital Cardiol; 1982; 12(10):729-35. PubMed ID: 7182212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled comparison of labetalol and propranolol in the management of severe hypertension.
    Pugsley DJ; Armstrong BK; Nassim MA; Beilin LJ
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):777-82. PubMed ID: 791331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of increasing doses of labetalol on blood pressure, plasma renin activity and aldosterone in hypertensive patients.
    Salvetti A; Pedrinelli R; Sassano P; Arzilli F
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():401s-404s. PubMed ID: 396086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with labetalol in hypertension.
    Bolli P; Waal-Manning J; Wood AJ; Simpson FO
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):765-71. PubMed ID: 791330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind trial of labetalol.
    Kane J; Gregg I; Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):737-41. PubMed ID: 791329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
    Rasmussen S; Nielsen PE
    Postgrad Med J; 1980; 56 Suppl 2():33-6. PubMed ID: 7433340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects.
    Mehta J; Feldman RL; Marx JD; Kelly GA
    Am J Med; 1983 Oct; 75(4A):32-9. PubMed ID: 6638039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.
    Ronne-Rasmussen JO; Andersen GS; Jensen NB; Andersson E
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):805-8. PubMed ID: 990157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.
    Thompson FD; Joekes AM; Hussein MM
    Br J Clin Pharmacol; 1979; 8(Suppl 2):129S-133S. PubMed ID: 526392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous labetalol in hypertensive patients given by fast and slow injection.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1978 May; 5(5):401-5. PubMed ID: 350248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of exercise on intra-arterial blood pressure and pulse rate before and during long-term high-dose treatment with labetalol in patients with severe, therapy-resistant hypertension.
    la Cour Petersen E; Kristensen BO
    Postgrad Med J; 1980; 56 Suppl 2():60-4. PubMed ID: 7433345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe essential hypertension with labetalol: effect on active and inactive renin.
    Hauger-Klevene JH
    Pharmatherapeutica; 1981; 3(1):46-54. PubMed ID: 7033992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.